MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer
Latest Information Update: 14 Jul 2024
At a glance
- Drugs Trastuzumab (Primary) ; Tucatinib (Primary)
- Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
- Focus Registrational; Therapeutic Use
- Acronyms MOUNTAINEER
- Sponsors Seagen
- 04 Jun 2024 Results (n=116, data cut-off: 02 Nov 2023) assessing the study endpoints at final analysis evaluating DOR per BICR, PFS per BICR, OS, and safety, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 09 Nov 2023 Status changed from active, no longer recruiting to completed.
- 24 Oct 2023 Results of exploratory analysis assessing the impact of concomitant baseline genomic alterations on the clinical activity of tucatinib plus trastuzumab, presented at the 48th European Society for Medical Oncology Congress.